A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-admin...
Saved in:
Main Author: | The MMR-158 Study Group (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
by: Tina Downey, et al.
Published: (2022) -
A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
by: Nitin Shah, et al.
Published: (2024) -
Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines
by: Md Ahsan Habib, et al.
Published: (2023) -
Hubungan vaksin Measles, Mumps, Rubella (MMR) dengan Kejadian Autisme
by: Elsye Souvriyanti, et al.
Published: (2016) -
A study to evaluate the role of intradermal and intralesional measles, mumps, rubella (MMR) vaccine in treatment of common warts
by: Pragya Gupta, et al.
Published: (2020)